These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 31753108)
1. Role of Heredity in Melanoma Susceptibility: A Primer for the Practicing Surgeon. Abdo JF; Sharma A; Sharma R Surg Clin North Am; 2020 Feb; 100(1):13-28. PubMed ID: 31753108 [TBL] [Abstract][Full Text] [Related]
2. [From gene to disease; from p16 to melanoma]. Gruis NA; Bergman W Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670 [TBL] [Abstract][Full Text] [Related]
3. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381 [TBL] [Abstract][Full Text] [Related]
4. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. Bruno W; Pastorino L; Ghiorzo P; Andreotti V; Martinuzzi C; Menin C; Elefanti L; Stagni C; Vecchiato A; Rodolfo M; Maurichi A; Manoukian S; De Giorgi V; Savarese I; Gensini F; Borgognoni L; Testori A; Spadola G; Mandalà M; Imberti G; Savoia P; Astrua C; Ronco AM; Farnetti A; Tibiletti MG; Lombardo M; Palmieri G; Ayala F; Ascierto P; Ghigliotti G; Muggianu M; Spagnolo F; Picasso V; Tanda ET; Queirolo P; Bianchi-Scarrà G J Am Acad Dermatol; 2016 Feb; 74(2):325-32. PubMed ID: 26775776 [TBL] [Abstract][Full Text] [Related]
5. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867 [TBL] [Abstract][Full Text] [Related]
6. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834 [TBL] [Abstract][Full Text] [Related]
7. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638 [TBL] [Abstract][Full Text] [Related]
8. Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway. Levin T; Mæhle L Fam Cancer; 2017 Apr; 16(2):257-265. PubMed ID: 27804060 [TBL] [Abstract][Full Text] [Related]
9. Melanoma-prone families: new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers. Gironi LC; Colombo E; Pasini B; Giorgione R; Farinelli P; Zottarelli F; Esposto E; Zavattaro E; Allara E; Ogliara P; Betti M; Dianzani I; Savoia P Arch Dermatol Res; 2018 Dec; 310(10):769-784. PubMed ID: 30218143 [TBL] [Abstract][Full Text] [Related]
10. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. Eskandarpour M; Hashemi J; Kanter L; Ringborg U; Platz A; Hansson J J Natl Cancer Inst; 2003 Jun; 95(11):790-8. PubMed ID: 12783933 [TBL] [Abstract][Full Text] [Related]